These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22271877)

  • 1. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
    Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
    Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
    Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
    J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Barni S
    Clin Lung Cancer; 2012 Mar; 13(2):107-14. PubMed ID: 22056888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
    Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
    Felip E; Rojo F; Reck M; Heller A; Klughammer B; Sala G; Cedres S; Peralta S; Maacke H; Foernzler D; Parera M; Möcks J; Saura C; Gatzemeier U; Baselga J
    Clin Cancer Res; 2008 Jun; 14(12):3867-74. PubMed ID: 18559607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
    Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
    Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
    Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
    Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
    J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.
    Ameratunga M; Pavlakis N; Gebski V; Broad A; Khasraw M
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):273-8. PubMed ID: 25135201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
    Liu Y; Zhang Y; Zhang L; Liu B; Wang Y; Zhou X; Li Y; Zhao Q; Gong Y; Zhou L; Zhu J; Ding Z; Wang J; Peng F; Huang M; Li L; Ren L; Lu Y
    Oncotarget; 2017 Jul; 8(30):49680-49688. PubMed ID: 28591695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
    Hirsch FR; Varella-Garcia M; Bunn PA; Di Maria MV; Veve R; Bremmes RM; Barón AE; Zeng C; Franklin WA
    J Clin Oncol; 2003 Oct; 21(20):3798-807. PubMed ID: 12953099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
    Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.